Every 10-Q that Kyverna Therapeutics (KYTX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow KYTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KYTX filings page.
Kyverna Therapeutics is a late-stage clinical immunology company developing CAR T therapies for neurologic autoimmune diseases, led by mivocabtagene autoleucel (miv-cel/KYV-101). For the six months ended June 30, 2026, the company reported a net loss of $78.0 million, an improvement from $86.7 million a year earlier, driven mainly by lower research and development expenses of $54.9 million versus $73.2 million, partially offset by higher general and administrative expenses of $26.1 million versus $18.6 million.
Cash, cash equivalents and marketable securities totaled $199.4 million at June 30, 2026, with net cash used in operating activities of $81.9 million in the first half. Management expects existing cash, an undrawn $125.0 million capacity under a term loan facility, and an at-the-market equity program to fund operations for at least 12 months. Clinically, Kyverna reported positive Phase 2 data in stiff person syndrome, initiated a rolling BLA submission supported by RMAT and orphan designations, advanced its Phase 3 trial in generalized myasthenia gravis, secured an ElevateBio commercial supply agreement, and received RMAT designation for non-active secondary progressive multiple sclerosis.
Kyverna Therapeutics (KYTX) filed its Q3 2025 10‑Q. The company reported a net loss of $36.8M for the quarter and $123.5M for the nine months ended September 30, driven by research and development of $30.5M in Q3 and $103.7M year‑to‑date, and general and administrative expenses of $8.3M in Q3 and $26.8M year‑to‑date. Interest income contributed $2.0M in Q3.
Liquidity remained solid with cash, cash equivalents and marketable securities of $171.1M as of September 30, 2025. Operating cash outflow was $120.2M year‑to‑date. Subsequent to quarter‑end, the company entered a term loan facility of up to $150.0M and drew $25.0M on November 3, 2025; the facility bears interest at 1‑Month CME Term SOFR (floor 3.75%) plus 5.00% and matures on October 1, 2030, with interest‑only payments through at least November 1, 2028.
Management estimates that, with the initial $25.0M loan funding, existing balances will fund operations for at least the next 12 months from issuance. As additional flexibility, a shelf registration allows offerings up to $250.0M, including an at‑the‑market program with $50.0M available as of quarter‑end. Shares outstanding were 43,796,170 as of October 31, 2025.
Kyverna Therapeutics is a clinical-stage biopharma developing CAR T cell therapies for autoimmune diseases. For the quarter ended June 30, 2025, the company reported a net loss of $42.1 million and a six-month net loss of $86.7 million, with net loss per share of $0.97 for the quarter. Accumulated deficit stood at $350.2 million. As of June 30, 2025, Kyverna held $53.4 million in cash and $158.2 million in available-for-sale marketable securities, totaling $211.7 million of liquidity; management estimates this funding is sufficient for at least the next 12 months and into 2027 under the current plan.
Operationally, Kyverna completed enrollment in its registrational Phase 2 KYSA-8 study for stiff person syndrome in Q2 2025 and expects data in the first half of 2026. The KYSA-6 trial in myasthenia gravis has completed enrollment, interim data are planned for Q4 2025, and the trial is being expanded to include a Phase 3 portion expected to begin enrollment by year-end 2025. The company also noted FDA alignment on CMC readiness and plans to support a BLA filing for SPS in the first half of 2026. The company faces securities class and derivative litigation; no loss accruals were recorded as of June 30, 2025.